Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype

• Published in: Pediatric pulmonology Vol. 56; no. 6; pp. 1496 - 1503
• Main Authors: McGarry, Meghan E., McColley, Susanna A.
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.06.2021
• Subjects: Cross-Sectional Studies; Cystic fibrosis; Cystic Fibrosis - drug therapy; Cystic Fibrosis - genetics; Cystic Fibrosis Transmembrane Conductance Regulator - genetics; epidemiology; Ethnicity - genetics; FDA approval; Genotype; Humans; Minority & ethnic groups; Minority Groups; Mutation; pharmacology; United States > US; epidemiology; cystic fibrosis; pharmacology

Background Cystic fibrosis transmembrane conductance regulator (CFTR) modulators are disease‐modifying medications for cystic fibrosis (CF) and are shown to be efficacious for only specific CFTR mutations. CFTR mutation frequency varies by ancestry, which is different from but related to demographic...